Similarly, early data from a phase 1 trial in patients with metastatic/unresectable EGFR tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutated NSCLC showed HER3-DXd had a manageable safety profile and clinically meaningful antitumor activity (NCT0326049) [19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.